Valvular & structural heart disease
Outcomes of transcatheter aortic valve implantation for native aortic valve regurgitation
Authors' conclusion
TAVI with NGD in PAVR patients is efficient and reasonably safe.
Study context
- Population
- Patients with grade III/IV pure native aortic valve regurgitation treated with transcatheter aortic valve implantation (TAVI) using new-generation devices, 2015–2021
- Participants
- 227 patients41 centres
- Outcome
- Primary safety endpoint: technical success (VARC-3); co-primary: composite of mortality, HF hospitalisation and valve reintervention
- Follow-up
- At last (co-primary)
Methodological detailsmulticentre, 41 centres, FRANCE-TAVI Registry
- Multicentre
- 41 centres
- FRANCE-TAVI Registry
Main finding
As reported in the abstract
Technical success (VARC-3; primary safety endpoint) and composite of mortality, HF hospitalisation and valve reintervention (co-primary)
Technical success
85.5%
Co-primary composite at 1 year
41.6%
IQR 34.4–49.6
Co-primary composite at 4 years
61.8%
IQR 52.4–71.2
Technical success independently predicted the co-primary endpoint, HR
0.45 (0.27-0.76); p=0.003 (95% CI)
Observational data: associations, not effects.
Further findings
Procedural results
- Second valve implantation, independent of valve type (p=0.82)
- 8.8%
- Device size ≥29 mm
- 73.0%
- Post-procedure residual aortic regurgitation grade ≥III
- 1.2%
Mortality and reintervention · 30 days
- Mortality
- 8.4%
- Reintervention
- 3.5%
Safety
Permanent pacemaker implantation
- Permanent pacemaker implantation (PPI) rate
- 36.0%
Original publication
Outcomes of transcatheter aortic valve implantation for native aortic valve regurgitation. EuroIntervention. Published 2 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →